Certara, Inc. CERT

Technology SIC 7372 - Services-Prepackaged Software NAICS Information › Publishing Industries › Software Publishers derived Nasdaq

We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development ("MIDD") in the global biopharmaceutical and biotech industry. MIDD is an approach that utilizes biological and statistical models derived from preclinical, clinical, and evidence data to inform decision-making in drug research and development, and commercialization. Biosimulation is a critical component of MIDD that uses computer-aided mathematical simulation of biological processes and systems to understand the action of a drug in a human body or a population of humans.

Biosimulation and hereby MIDD can increase the probability of success in bringing a new drug to market, accelerate its development and decrease the costs of drug development. There are many examples of currently approved drugs where models were successfully used in discovery, preclinical, first-in-human dose predictions, clinical trial simulations and protocol design, and for drug interaction label claims. Biosimulation is also used to support drug development beyond the approval stage; examples include determining formulation or manufacturing changes and label extensions. In addition, MIDD strategies are increasingly utilized to help predict commercial success, a critical part of the drug research and development process as new products must be both approved by regulators and adopted by the market.

Last close 10.33 2026-10-23
Market cap $1.58B 2026-06-30 share count
52-week range 4.45 - 12.62

Valuation FY2025 figures against the last close

P/S3.8x
P/E—
P/FCF16.7x
EV/EBITDA17.5x
Dividend yield—
Diluted EPS-0.01

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue $418.8M$385.1M$354.3M$335.6M$286.1M$243.5M$208.5M—
Cost of revenue ——$141.0M$132.6M$111.6M$100.8M$79.8M—
Gross profit ——$213.3M$203.1M$174.5M$142.8M$128.7M—
R&D $41.0M$37.1M$34.2M$28.2M$20.4M$19.6M$11.6M—
SG&A $85.4M$94.2M$95.4M$71.8M$79.5M$88.5M$47.9M—
Total operating expenses $236.7M$232.4M$254.1M$170.5M$160.9M$167.2M$109.1M—
Operating income $21.0M-$1.7M-$40.8M$32.5M$13.6M-$24.4M$19.6M—
Interest expense $19.7M$21.5M$22.9M$17.8M$16.8M$25.3M$28.0M—
Pre-tax income $7.6M-$17.2M-$55.1M$18.8M-$3.4M-$50.2M-$9.2M—
Income tax $9.2M$5.1M$214.0K$4.0M$9.9M$784.0K$225.0K—
Net income -$1.6M-$12.1M-$55.4M$14.7M-$13.3M-$49.4M-$8.9M—
EPS, basic -0.01-0.08-0.350.09-0.09-0.37-0.07—
EPS, diluted -0.01-0.08-0.350.09-0.09-0.37-0.07—
Shares, diluted (wtd. avg.) 160.4M160.4M158.9M159.4M149.8M133.2M132.4M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $189.4M$179.2M$235.0M$239.7M$186.6M$273.3M$29.8M$12.2M
Receivables $94.6M$90.6M$75.4M$72.2M$60.2M$46.4M——
Total current assets $315.1M$310.9M$340.2M$342.3M$274.7M$346.6M——
Property, plant and equipment $1.9M$2.2M$2.7M$2.4M$2.9M———
Goodwill $773.3M$757.0M$716.3M$717.7M$703.4M$518.6M$515.0M—
Other intangibles $447.5M$485.2M$487.0M$486.8M$511.8M$396.4M——
Total assets $1.56B$1.58B$1.56B$1.57B$1.51B$1.27B——
Accounts payable $3.4M$3.5M$5.2M$7.5M$7.5M$6.4M——
Short-term debt $3.0M$3.0M$3.0M$3.0M$3.0M$4.7M——
Total current liabilities $153.4M$146.1M$130.0M$103.2M$92.2M$75.3M——
Long-term debt $290.1M$292.4M$288.2M$290.0M$291.7M$294.1M——
Total liabilities $493.8M$516.4M$516.3M$493.3M$469.9M$447.3M——
Retained earnings -$129.9M-$128.3M-$116.2M-$60.9M-$75.6M-$62.3M——
Total equity $1.06B$1.06B$1.05B$1.08B$1.04B$822.1M$492.0M$492.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow $96.3M$80.5M$82.8M$92.5M$60.4M$44.8M$38.0M—
Depreciation and amortisation $75.2M$68.0M$56.1M$1.7M$2.1M$2.4M$2.6M—
Capital expenditure $1.8M$1.6M$1.8M$1.4M$1.1M$863.0K$2.1M—
Investing cash flow -$26.6M-$112.4M-$79.5M-$27.8M-$269.9M-$8.6M-$9.5M—
Financing cash flow -$64.0M-$21.0M-$9.4M-$7.4M$123.4M$208.2M-$8.5M—
Buybacks $42.6M$0$0——$1.1M$703.0K—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001827090-26-000011.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M 0 200M 400M 600M Revenue, FY2019: 208.5M Gross profit, FY2019: 128.7M Net income, FY2019: -8.9M Revenue, FY2020: 243.5M Gross profit, FY2020: 142.8M Net income, FY2020: -49.4M Revenue, FY2021: 286.1M Gross profit, FY2021: 174.5M Net income, FY2021: -13.3M Revenue, FY2022: 335.6M Gross profit, FY2022: 203.1M Net income, FY2022: 14.7M Revenue, FY2023: 354.3M Gross profit, FY2023: 213.3M Net income, FY2023: -55.4M Revenue, FY2024: 385.1M Net income, FY2024: -12.1M Revenue, FY2025: 418.8M Net income, FY2025: -1.6M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $208.5M $243.5M $286.1M $335.6M $354.3M $385.1M $418.8M
Gross profit — $128.7M $142.8M $174.5M $203.1M $213.3M — —
Net income — -$8.9M -$49.4M -$13.3M $14.7M -$55.4M -$12.1M -$1.6M

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 7372

TickerCompanyMarket capP/ERevenue growth
MSFT MICROSOFT CORP $3.89T 29.2x 17.8%
PLTR Palantir Technologies Inc. $472.16B 312.3x 56.2%
ORCL ORACLE CORP $363.40B 21.6x 17.3%
CRWD CrowdStrike Holdings, Inc. $263.73B — 21.7%
SHOP SHOPIFY INC. $218.48B 179.4x 30.1%
CRM Salesforce, Inc. $204.57B 31.9x 9.6%
NOW ServiceNow, Inc. $164.36B 95.2x 20.9%
NET Cloudflare, Inc. $115.42B — 29.8%